Karo Bio officially names Per Bengtsson CEO
This article was originally published in Scrip
Karo Bio, a pharma company with development projects in indication areas including cardiovascular and metabolic disease, neuropsychiatry and inflammation, has appointed Per Bengtsson CEO. Mr Bengtsson has been acting CEO since May when Fredrik Lindgren left the company (scripintelligence.com, 27 May 2011). He was previously CEO of Probi.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.